NEW YORK, July 24, 2020 /PRNewswire/ --
If you own shares in any of the
companies listed above and
would like to discuss our investigations or have any questions
concerning
this notice or your rights or interests, please contact:
Joshua Rubin,
Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com
Dime Community Bancshares, Inc. (NASDAQ: DCOM)
WeissLaw LLP is investigating possible breaches of fiduciary
duty and other violations of law by the board of directors of
Dime Community Bancshares, Inc. (NASDAQ: DCOM) in
connection with the proposed merger of the company with Bridge
Bancorp, Inc. ("BDGE"). Under the terms of the merger
agreement, DCOM shareholders will receive 0.6480 shares of BDGE
common stock for each share of DCOM that they hold, representing
implied per-share merger consideration of $11.94 based upon BDGE's July 23, 2020 closing price of $18.43. If you own DCOM shares and wish to
discuss this investigation or your rights, please call us at one of
the numbers listed above or visit our website:
https://weisslawllp.com/dime-community-bancshares-inc/
Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN)
WeissLaw LLP is investigating possible breaches of fiduciary
duty and other violations of law by the board of directors of
Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN) in
connection with the proposed stock-for-stock merger of the company
with privately-held Ocuphire Pharma ("Ocuphire"). Upon
consummation of the proposed merger, Ocuphire will own at least
85.7% of the newly-combined company, with REXN stockholders owning
the remaining 14.3%. Under the terms of the acquisition
agreement, REXN will also be issued contingent value rights ("CVR")
representing the right to receive (i) 90% of payments received by
the combined company pursuant to its licensing agreements with
BioSense Global LLC and Zhejiang HaiChang Biotechnology Co., Ltd.
during the 15-year period after the closing of the merger; and (ii)
75% of the proceeds received by the combined company from the
monetization of REXN existing intellectual property during the
10-year period after the merger's close. If you own
REXN shares and wish to discuss this investigation or your rights,
please call us at one of the numbers listed above or visit our
website:
https://weisslawllp.com/rexahn-pharmaceuticals-inc/
View original content to download
multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-reminds-dcom-and-rexn-shareholders-about-its-ongoing-investigations-301099690.html
SOURCE WeissLaw LLP